Cadila Healthcare is currently trading at Rs. 447.70, down by 2.95 points or 0.65% from its previous closing of Rs. 450.65 on the BSE.
The scrip opened at Rs. 452.00 and has touched a high and low of Rs. 454.85 and Rs. 446.25 respectively. So far 28983 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 460.00 on 17-Feb-2017 and a 52 week low of Rs. 305.00 on 12-Apr-2016.
Last one week high and low of the scrip stood at Rs. 455.55 and Rs. 439.15 respectively. The current market cap of the company is Rs. 45812.48 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.18% and 8.03% respectively.
Cadila Healthcare is recalling 9,561 bottles Atenolol tablets USP, 50 mg. The reason for recall is presence of foreign tablets/ capsules ‘customer complaint that a bottle of atenolol 50 mg tablets USP contained a paroxetine 20 mg tablet’. Atenolol tablets are used for treatment of hypertension. The firm initiated nationwide recall in the USA and Puerto Rico recall is also a class II recall.
As per the United States Food and Drug Administration (USFDA), a class II recall is initiated ‘in a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.